---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-26-000040"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2026-10-15T20:10:52+00:00"
generated_at: "2026-10-15T20:12:04.574505+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus stockholders approve merger with Indivior; 48.25M votes for, 235,601 against

## Summary
- Proposal 1 (adoption of Merger Agreement) passed: 48,249,532 votes for, 235,601 against, 67,004 abstained, no broker non-votes.
- Under the deal, Artemis Merger Sub, Inc. merges into Supernus, which survives as a wholly-owned subsidiary of Indivior Pharmaceuticals Inc.
- Proposal 2 (non-binding golden-parachute compensation for named executive officers) passed 32,688,410 for vs 15,847,350 against, 16,377 abstained.
- Special Meeting held October 15, 2026; 58,224,143 shares outstanding and entitled to vote as of the September 4, 2026 record date.
- Proxy statement for the Special Meeting was filed with the SEC on September 11, 2026; merger closing conditions not detailed in this filing.

## SEC filing metadata
- accession: 0001356576-26-000040
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2026-10-15T20:10:52+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000040/0001356576-26-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000040/supn-20261015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-26-000040
- JSON: https://secwatch.observer/filing/0001356576-26-000040.json
- Plain text: https://secwatch.observer/filing/0001356576-26-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.